Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 6, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on October 5, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 4,756 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on October 6, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same capacity as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the total number of shares transferred (4,756) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (October 5, 2005) versus the date of notification to the company (October 6, 2005).
- Review the status of the GSK Trust as a discretionary trust for current and former employees.
- Identify the specific directors with interests in the trust shares: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.